Barclays (LON:BARC) analyst Steven Valiquette maintained a Buy rating on Cardinal Health (NYSE:CAH) on Friday, setting a price target of $72, which is approximately 29.87% above the present share price of $55.44.
Valiquette expects Cardinal Health to post earnings per share (EPS) of -$0.86 for the first quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Cardinal Health, with an average price target of $65.
The analysts price targets range from a high of $72 to a low of $58.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $39.07 billion and a net profit of $460 million. The company's market cap is $16.27 billion.
According to TipRanks.com, Barclays analyst Steven Valiquette is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.1% and a 56.82% success rate.
Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The company operates through the following segments: Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes cardinal health branded medical, surgical and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.